Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials

Published:2020-02-01 Issue:2 Volume:180 Page:269-278
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Li Meng,Xiong Yiting,Liao Chen,He Yunyan,Duan Sijia,Yi Fengming,Wei Yiping,Zhang Wenxiong^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangxi Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-020-05551-3.pdf

Reference30 articles.

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

2. Harbeck N, Gnant M (2017) Breast cancer. The Lancet 389(10074):1134–1150

3. Early Breast Cancer Trialists Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet 386(10001):1341–1352

4. Van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM et al (2019) Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. Int J Cancer 145(1):274–283

5. Hanamura T, Hayashi S (2017) Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications. Breast Cancer 25(4):379–391

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement;Cancers;2021-11-11